All In Biotech

NDA 218201 · Sebela Womens Hlth

Miudella

Copper · Intrauterine · Copper-containing Intrauterine Device

Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Feb 24, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

158

26 Phase 3, 16 recruiting

FAERS reports

737

493 serious, 40 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION Improper insertion of intrauterine systems, including Miudella, increases the risk of complications [see Warnings and Precautions (5.1) ] . Proper training prior to first use of Miudella can minimize the risk of improper Miudella insertion [see Warnings and Precautions (5.1) ]. Miudella is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Miudella REMS program to ensure healthcare providers are trained on the proper insertion of Miudella prior to first use [see Warnings and Precautions (5.2) ]. WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION Improper insertion of intrauterine systems, including Miudella, increases the risk of complications [see Warnings and Precautions (5.1) ]. Proper training prior to first use of Miudella can minimize the risk of improper...

What it is approved for

From the label in effect Oct 7, 2026.

Miudella is indicated for prevention of pregnancy in females of reproductive potential for up to 3 years. Miudella is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 3 years.( 1 )

Mechanism: Copper continuously released into the uterine cavity contributes to the contraceptive effectiveness of Miudella. Mechanism(s) by which copper enhances contraceptive efficacy include interference with sperm transport and fertilization of an egg.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 24, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetter
1 products under this application
  • MIUDELLA · COPPER N/A · SYSTEM, INTRAUTERINE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Copper" as an intervention, any sponsor and status, largest first.

All 158 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue75
  • off label use74
  • headache64
  • nausea64
  • pain62
  • diarrhoea61
  • drug ineffective52
  • weight decreased49
  • malaise43
  • abdominal pain40
  • anaemia36
  • dizziness36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20054
20061
20073
20084
20096
20109
201114
201213
201321
201421
201532
201660
201723
201845
201956
202052
202163
202269
202362
202463
202567
202648

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,074 on PubMed

Sponsor: Sebela Womens Hlth

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.